Boiron's Sales Grow Double-Digits In 2022 Despite Difficult End To Year
Executive Summary
French homeopathy specialist Boiron enjoyed a good 2022 after a few challenging years as a result of COVID-19 and France's decision to exclude homeopathic medicines from health insurance coverage.
You may also be interested in...
France's Boiron Reaping The Benefits Of Product Investments
Boiron's decision to diversify its portfolio away from non-proprietary homeopathic medicines is paying off, with sales for the opening nine months of 2022 up by a quarter, driven by new product launches in categories such as cosmetics and dietary supplements.
Boiron Partners With Galenica's Verfora In Switzerland
France's Boiron has granted Galenica's Verfora the rights to distribute in Switzerland its portfolio of over 800 products as it looks to turnaround its business and make cost savings following the collapse of homeopathy sales in its home market.
UK Rejects Blood Glucose Health Claim For White Mulberry Supplement
The UK Nutrition and Health Claims Committee has rejected the health claim “clinically proven in assisting healthy blood glucose levels” in the target population of type 2 diabetics for Ascarit’s white mulberry-based dietary supplement.